Results 91 to 100 of about 209,193 (336)

Pigment Epithelium-Derived Factor and its Phosphomimetic Mutant Induce JNK-Dependent Apoptosis and P38-Mediated Migration Arrest

open access: yesCellular Physiology and Biochemistry, 2018
Background/Aims: Pigment epithelium-derived factor (PEDF) is a potent endogenous inhibitor of angiogenesis, and a promising anticancer agent. We have previously shown that PEDF can be phosphorylated, and that distinct phosphorylations differentially ...
Alexander Konson   +3 more
doaj   +1 more source

Mucin-inspired, high molecular weight virus binding inhibitors show biphasic binding behavior to influenza A viruses [PDF]

open access: yesarXiv, 2020
Multivalent virus binding inhibitors are a promising new class of antivirals, preventing virus infection of cells by inhibiting the first step in the viral infection cycle - binding of viruses to the cell surface. The design of multivalent virus binding inhibitors is complex as many properties, such as inhibitor size and functionalization with virus ...
arxiv  

Red blood cells could protect miRNAs from degradation or loss thanks to Argonaute 2 binding

open access: yesFEBS Open Bio, EarlyView.
The present work investigates the presence and the stability of miRNAs into RBCs, both native and engineered. The observed stability is due to the Ago2 bound resulting in minimal RISC. Indeed, if the miRNA‐Ago2 complex is present, miRNAs are protected from release or degradation and they are biologically active. Thus, RBCs can act as miRNA carriers for
Elena Perla   +4 more
wiley   +1 more source

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

open access: yesFEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik   +3 more
wiley   +1 more source

Modeling Tumor Angiogenesis with Cellular Automata [PDF]

open access: yesarXiv, 2019
Angiogenesis is the formation of new blood vessels from the existing vessels. During tumour angiogenesis, tumour cells secret a number of chemical substrates called tumour angiogenic factors (TAFs). These factors diffuse through the extracellular matrix (ECM) and degrade the basement membrane of nearby vasculature.
arxiv  

Comparative single‐cell transcriptomic profiling of patient‐derived renal carcinoma cells in cellular and animal models of kidney cancer

open access: yesFEBS Open Bio, EarlyView.
We generated and characterized clear cell renal cell carcinoma models using the patient‐derived RCC243 cell line—including cell culture, orthotopic, and metastatic tumors—via single‐cell RNA‐sequencing for comparisons between models and patient tumor datasets.
Richard Huang   +9 more
wiley   +1 more source

Brain-Specific Angiogenesis Inhibitor 3 Is Expressed in the Cochlea and Is Necessary for Hearing Function in Mice. [PDF]

open access: yesInt J Mol Sci, 2023
Saegusa C   +8 more
europepmc   +1 more source

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

open access: yesFEBS Open Bio, EarlyView.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli   +15 more
wiley   +1 more source

On the efficiency of treatment of wet age-related macular degeneration with Lucentis

open access: yesРоссийский офтальмологический журнал, 2018
The paper studies the efficiency of ranibizumab (Lucentis, Novartis Pharma), a VEGF blocker inhibiting angiogenesis, in patients with wet age macular degeneration (AMD) at different stages of the pathological process.
E. M. Kasimov   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy